AZILECT - Drug for Parkinson’s Disease

Biomedical/Life Sciences

Prof. Moussa B.H. Youdim, Prof. John Finberg
Technion – Israel Institute of Technology

The researchers discovered the molecule “rasagiline” in the 1970s. Now the drug is marketed globally as AZILECT. AZILECT is indicated for the treatment of Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa). AZILECT slows down neuron death and the progression of Parkinson’s disease.